# Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

> **NCT05207709** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 456 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Ribociclib + Letrozole OR Fulvestrant
- **DRUG:** Palbociclib + Letrozole OR Fulvestrant
- **DRUG:** Paclitaxel +/- Tislelizumab

## Key facts

- **NCT ID:** NCT05207709
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-28
- **Primary completion:** 2026-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 456 (ESTIMATED)
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05207709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05207709, "Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05207709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*